Latest news with #Buse
Time of India
04-05-2025
- Health
- Time of India
Study finds men more likely to fall sick, die from 3 common health conditions
New Delhi: Men in many countries are more likely to fall sick and die from hypertension , diabetes , and HIV/AIDS as compared to women, according to a new study. However, compared to women, men were found to be less likely to seek medical care and adhere to treatment for these common health conditions due to norms related to masculinity and healthcare financing. Men were also more likely to smoke, while women were more likely to be obese and engage in unsafe sex, the study, published in the journal PLOS Medicine , found. The research highlights sex-based differences at each step of the "health pathway", which includes being exposed to a risk factor -- such as smoking -- developing a condition, diagnosis, treatment and death, study authors said. "Most of these differences are not explained by sex (biology) alone, but by socially-constructed gender -- highlighting the importance of taking a gender justice approach to reducing health inequities. A gender analysis can help to shape systems of health for all," Kent Buse, co-founder of Global 50/50, a UK-based research initiative seeking to achieve gender equality in global health , said. The findings are in line with those from previous studies showing men using fewer preventive, diagnostic, and treatment services for conditions such as HIV and COVID-19, compared to women. The study found that men and women received different care for hypertension in 200 countries. Also in 39 countries such as Afghanistan, Bangladesh, Ecuador and Ethiopia, men and women received different care for diabetes, and in 76 countries, including Australia, Chile, Italy and Lesotho, they received different care for HIV. Overall, the authors said strategies need to be developed for encouraging men to participate in preventive and health care services. "We have long advocated the benefits of publishing sex disaggregated data. As our Gendered Health Pathways demonstrates, such data can reveal where the health journeys of men and women diverge be it in relation to the risk factors they are exposed to, their health care seeking behaviours or their experiences in health care systems. That is an important first step towards health equity ," Buse said. "Males had significantly higher prevalence rates of conditions in 56 per cent of countries for HIV and AIDS, 30 per cent for diabetes, and four per cent for hypertension," the authors wrote. "Females, on the other hand, had significantly higher prevalence rates of conditions in 14 per cent of countries for HIV and AIDS, five per cent for diabetes, and only in India for hypertension," they wrote. Further, compared to women, death rates were found to be higher among men in 131 countries (64 per cent) for HIV/AIDS, 107 for hypertension (53 per cent) and 100 for diabetes (49 per cent). Death rates among women were higher, compared to men, in 25 countries for HIV/AIDS, nine for diabetes and only in the United Arab Emirates for hypertension, the study found. Women were also seen to have higher rates of diagnosis, treatment, and control. For the study, data on risk factors, disease prevalence, and death rates were obtained from the Global Burden of Disease (GBD) dataset.
&w=3840&q=100)
Business Standard
04-05-2025
- Health
- Business Standard
Study finds men more likely to fall sick, die from 3 common health issues
Men in many countries are more likely to fall sick and die from hypertension, diabetes, and HIV/AIDS as compared to women, according to a new study. However, compared to women, men were found to be less likely to seek medical care and adhere to treatment for these common health conditions due to norms related to masculinity and healthcare financing. Men were also more likely to smoke, while women were more likely to be obese and engage in unsafe sex, the study, published in the journal PLOS Medicine, found. The research highlights sex-based differences at each step of the "health pathway", which includes being exposed to a risk factor -- such as smoking -- developing a condition, diagnosis, treatment and death, study authors said. "Most of these differences are not explained by sex (biology) alone, but by socially-constructed gender -- highlighting the importance of taking a gender justice approach to reducing health inequities. A gender analysis can help to shape systems of health for all," Kent Buse, co-founder of Global 50/50, a UK-based research initiative seeking to achieve gender equality in global health, said. The findings are in line with those from previous studies showing men using fewer preventive, diagnostic, and treatment services for conditions such as HIV and COVID-19, compared to women. The study found that men and women received different care for hypertension in 200 countries. Also in 39 countries such as Afghanistan, Bangladesh, Ecuador and Ethiopia, men and women received different care for diabetes, and in 76 countries, including Australia, Chile, Italy and Lesotho, they received different care for HIV. Overall, the authors said strategies need to be developed for encouraging men to participate in preventive and health care services. "We have long advocated the benefits of publishing sex disaggregated data. As our Gendered Health Pathways demonstrates, such data can reveal where the health journeys of men and women diverge be it in relation to the risk factors they are exposed to, their health care seeking behaviours or their experiences in health care systems. That is an important first step towards health equity," Buse said. "Males had significantly higher prevalence rates of conditions in 56 per cent of countries for HIV and AIDS, 30 per cent for diabetes, and four per cent for hypertension," the authors wrote. "Females, on the other hand, had significantly higher prevalence rates of conditions in 14 per cent of countries for HIV and AIDS, five per cent for diabetes, and only in India for hypertension," they wrote. Further, compared to women, death rates were found to be higher among men in 131 countries (64 per cent) for HIV/AIDS, 107 for hypertension (53 per cent) and 100 for diabetes (49 per cent). Death rates among women were higher, compared to men, in 25 countries for HIV/AIDS, nine for diabetes and only in the United Arab Emirates for hypertension, the study found. Women were also seen to have higher rates of diagnosis, treatment, and control. For the study, data on risk factors, disease prevalence, and death rates were obtained from the Global Burden of Disease (GBD) dataset.
USA Today
22-02-2025
- Sport
- USA Today
How to Watch Ignacio Buse vs. Laslo Djere at the 2025 Movistar Chile Open: Live Stream, TV Channel
In the Movistar Chile Open Round of 32 on Monday, we have a matchup of No. 98-ranked Laslo Djere against No. 230 Ignacio Buse. His last time out, Buse fell to Dominik Koepfer 6-2, 3-6, 6-7 in the qualifying round at the Australian Open on January 7, 2025. Djere's most recent match on February 15, 2025 was a three-set defeat by Joao Fonseca 6-7, 7-5, 1-6 in the semifinals at the Argentina Open. Watch Tennis Channel on Fubo! Ignacio Buse vs. Laslo Djere: live stream info & TV channel Tournament: Movistar Chile Open Movistar Chile Open Round: Round of 32 Round of 32 Date: Monday, February 24 Monday, February 24 Live Stream: Watch Tennis Channel on Fubo Watch Tennis Channel on Fubo Court Surface: Clay Ignacio Buse vs. Laslo Djere matchup stats Buse is 3-3 on clay over the past 12 months. Buse has won 65.5% of his service games on clay over the past year and 32.5% of his return games. Buse has converted 26 of 67 break points on clay (38.8%) over the past year and is 117th in break points won. Buse was defeated in the Qualification Round 1 of his most recent tournament (the Australian Open) 6-2, 3-6, 6-7 by No. 123-ranked Koepfer on January 7. The 29-year-old Djere, who is seeking his first tournament win on clay in 2025, is 7-6 over the past 12 months on that surface. Djere is 133-for-163 in service games on clay (winning 81.6%) and 40-for-172 in return games (23.3%). Djere has won 41.7% of break points on clay courts (30 out of 72) to rank 94th. In his last tournament (the Argentina Open) on February 15, Djere squared off against Fonseca in the semifinals and lost 6-7, 7-5, 1-6. Tennis odds courtesy of BetMGM Sportsbook. Odds updated Saturday at 3:56 PM ET. For a full list of sports betting odds, access USA TODAY Sports Betting Scores Odds Hub. Gannett may earn revenue from sports betting operators for audience referrals to betting services. Sports betting operators have no influence over nor are any such revenues in any way dependent on or linked to the newsrooms or news coverage. Terms apply, see operator site for Terms and Conditions. If you or someone you know has a gambling problem, help is available. Call the National Council on Problem Gambling 24/7 at 1-800-GAMBLER (NJ, OH), 1-800-522-4700 (CO), 1-800-BETS-OFF (IA), 1-800-9-WITH-IT (IN). Must be 21 or older to gamble. Sports betting and gambling are not legal in all locations. Be sure to comply with laws applicable where you reside. We occasionally recommend interesting products and services. If you make a purchase by clicking one of the links, we may earn an affiliate fee. FTW operates independently, though, and this doesn't influence our coverage.
New York Times
10-02-2025
- Health
- New York Times
The Physicians Really Are Healing Themselves, With Ozempic
When Dr. C. Michael Gibson, a cardiologist at Harvard Medical School, goes to heart disease meetings, he can't help noticing a change. 'We will sit around at dinner and halfway through the meal, we will simultaneously push our plates away,' Dr. Gibson said. 'We look at each other and laugh and say, 'You, too?'' They share what is becoming an open secret: They tried for years to control their weight but are now taking the new obesity drugs manufactured by Eli Lilly and Novo Nordisk. Dr. Robert Califf, the former chief of the Food and Drug Administration, says he hardly recognizes his colleagues. So many are now so thin. 'Looking good,' he says he tells his fellow cardiologists at conferences and meetings. There are no studies documenting the percentage of doctors taking the drugs. But physicians 'are a good litmus test for drugs that are highly effective,' Dr. Califf said. If doctors who read the papers describing clinical-trial results are rushing to get a new drug, that is an indication that it's really promising. His colleagues' use of Wegovy and Zepbound reminds him of the use of statins, drugs that lower cholesterol, in their early days. Cardiologists, who were most familiar with the consequences of high cholesterol levels, were among the first to take the drugs in large numbers. Many newly thin cardiologists and diabetes specialists, like so many of their patients, had risk factors for heart disease. Or their blood sugar was creeping up. Or just the physical strain of carrying excess weight made everyday life burdensome. They say they like their new looks but also their new health and energy. In a way, they feel like members of a club. Four years ago, Dr. Darren McGuire, a cardiologist at the University of Texas Southwestern, was struggling with obesity and Type 2 diabetes. Then he started taking Ozempic, the Novo Nordisk diabetes drug that is sold under the name Wegovy for obesity. He later switched to Mounjaro, from Eli Lilly, which is sold as Zepbound for obesity. He lost 30 percent of his weight and got his blood sugar under control. Now, he said, he's 'feeling better than ever.' He is also struck by the number of colleagues who seem to be using the medications. 'People look pretty different,' said Dr. McGuire, who is on advisory boards for Novo Nordisk and Eli Lilly. 'It is amazing.' He described one prominent diabetes specialist, Dr. John Buse of the University of North Carolina, who 'has shrunk away.' Not quite, Dr. Buse said. But, he said, 'I lost 25 percent of my body weight and it totally changed my life.' He had struggled with his size since childhood, gaining, losing and then gaining weight again. When he dieted, he 'would get crazy hungry,' Dr. Buse said. With Wegovy, he said, his weight dropped effortlessly until he reached his goal. Then his appetite returned, which was scary. But instead of regaining pounds, he maintained a consistent weight as he continued to take the drug. Like other patients, he found that taking the drugs eliminated most of his desire to drink alcohol. Before he started Wegovy, he often would have two or three drinks with dinner. Now he has one, or none. Dr. Buse, who is a consultant for Novo Nordisk and Eli Lilly, said that he did not often ask people at diabetes meetings if they were taking one of the drugs but that 'there are people who have changed a lot.' He said he would 'bet dollars to doughnuts' that they were on weight-loss medication. Some cardiologists are still 'in the closet,' Dr. Gibson said. One is a cardiologist in Boston. She said the person who prescribed Ozempic for her was also a female cardiologist who was taking it. She asked not to be identified because she had told only a few people she was on the drug. She was trying to keep her medical information private, although she suspected that her colleagues might have guessed. She added that she was pretty sure she knew who else was taking one of the drugs. 'Yes, you can definitely tell,' she said. 'And when you go to dinners, you can definitely see. We eat, like, an eighth of our meal. I know what's going on here.' The doctors know they are privileged. At first, Dr. Buse's health insurance paid for his Wegovy. But soon North Carolina stopped paying for obesity drugs for state employees, so he paid out of pocket. With a list price of $1,349 a month, it was a major expense. Then, at a meeting in Europe, he asked a colleague to prescribe Wegovy for him and got a six-month supply. Dr. Buse was able to purchase Wegovy for a quarter of what it cost in the United States. The doctors also know how to advocate for themselves and navigate the medical system better than many of their patients do. Dr. McGuire's insurer initially declined to pay for his drugs. 'I had to appeal,' he said. 'I have a relationship with a primary care physician and know when to keep pushing.' His insurer agreed to pay. Dr. Gibson said that his insurer had paid without issue and that he wanted to discuss his decision to take Wegovy openly. (He recently switched to Lilly's Zepbound, also covered by his insurance, because it elicits an even greater weight loss.) 'A lot of people are of the mind-set that it is shameful, that it is cheating to use a drug,' Dr. Gibson said. But the obesity drugs changed his life, he said: 'It's the greatest thing I ever did.' And even Zepbound, powerful as it is, is just the beginning, Dr. Gibson said. 'There are 120 new agents coming along,' he noted, referring to drugs in clinical trials. 'I look forward to ones that may have even better safety and effectiveness.'
